EMA Authorised: Pemetrexed Baxter (pemetrexed disodium heptahydrate) — Baxter Holding B.V.

View source ↗

Summary

The EMA authorised Pemetrexed Baxter (pemetrexed disodium heptahydrate) for non-small cell lung carcinoma and mesothelioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mesothelioma
• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed Baxter (pemetrexed disodium heptahydrate)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung;Mesothelioma. MAH: Baxter Holding B.V.. Decision date: 09/12/2022